Kynapid Gets Panel Endorsement For Narrow Approval Due To Small Data Set

A restricted indication was strongly recommended by Cardiovascular and Renal Drugs Advisory Committee members to offset the uncertainty of adverse events with Astellas/Cardiome's Kynapid (vernakalant), especially since the atrial fibrillation product will likely be used in critical care situations like emergency rooms rather than by specialists